2021
Expression of PON2 isoforms varies among brain regions in male and female African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Expression of PON2 isoforms varies among brain regions in male and female African green monkeys. Free Radical Biology And Medicine 2021, 178: 215-218. PMID: 34890766, PMCID: PMC8760629, DOI: 10.1016/j.freeradbiomed.2021.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAryldialkylphosphataseBrainChlorocebus aethiopsDorsolateral Prefrontal CortexFemaleMaleOxidative StressProtein IsoformsConceptsAfrican green monkeysParkinson's diseaseBrain regionsParaoxonase 2Different brain regionsFemale monkeysGreen monkeysPON2 expressionOxidative stress-related neurodegenerative disordersFemale African green monkeysNeurodegenerative disordersMale African green monkeysOxidative stressPON2 protein expressionAnti-inflammatory propertiesExpression levelsSignificant differencesBrain tissue samplesDorsolateral prefrontal cortexNeuroprotective strategiesWestern blotting techniquesDopaminergic neuronsPON2 proteinPrimate brainProtective rolePioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAryldialkylphosphataseBrainFemaleMitochondriaNeurodegenerative DiseasesNeuroprotective AgentsOxidative StressPioglitazonePrimatesSex FactorsConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brainSex-based disparity in paraoxonase-2 expression in the brains of African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Sex-based disparity in paraoxonase-2 expression in the brains of African green monkeys. Free Radical Biology And Medicine 2021, 167: 201-204. PMID: 33722626, PMCID: PMC8096713, DOI: 10.1016/j.freeradbiomed.2021.03.003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAryldialkylphosphataseBrainChlorocebus aethiopsFemaleMaleMitochondriaOxidative StressReactive Oxygen SpeciesConceptsAfrican green monkeysParaoxonase 2Parkinson's diseaseBrain regionsGreen monkeysOxidative stressReactive oxygen speciesAnti-inflammatory propertiesSex-based disparitiesParaoxonase-2 expressionDifferent brain regionsNigrostriatal systemPON2 expressionDevelopment of therapeuticsNeurodegenerative disordersDiseaseProtein levelsROS levelsLower ROS levelsMitochondrial performanceSex-based variationDisordersMonkeysOxygen speciesMales
2020
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising target